Ocugen

MALVERN, Pa., USA — April 1, 2026 Ocugen, Inc. has announced the early completion of dosing in its Phase...

MALVERN, Pennsylvania, USA | March 24, 2026 In a major breakthrough for retinal disease treatment, Ocugen, Inc. has announced...

MALVERN, Pa., January 12, 2026 — Ocugen, Inc. announced the peer-reviewed publication of positive Phase 1 GARDian1 clinical trial...